Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$21.41
Mkt Cap
$1.451B
52W Low
$18.7
52W High
$94.9
52W Position info
14% above low
Off High info
77% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

GPCR is trading near its 52-week low of $18.7 (14% above the low).

Summary

Structure Therapeutics posted a Q3 2026 net loss of $144.8M versus $65.7M a year earlier on rising Phase 3 costs, backed by $1.2B in cash it says funds operations through 2028. The 10-Q also discloses the CTO's resignation and a new Chief Commercial Officer's compensation package.


Key Events · Earnings and Guidance · GPCR

  • Q3 Net Loss Widens to $144.8M

    Net loss was $144.8M versus $65.7M in Q3 2025, including $12.7M of non-cash share-based compensation.

  • R&D Spend Nearly Doubles

    R&D rose to $134.6M from $59.0M a year earlier on clinical trial, preclinical and employee costs; G&A rose to $21.8M from $14.8M.

  • $1.2B Cash Funds Operations Through 2028

    Cash, cash equivalents and short-term investments totaled $1.2B at September 30, 2026, down from $1.3B at June 30, 2026, funding milestones through end-2028 excluding pre-commercialization costs.

  • Phase 3 Topline Slated for 2H 2028

    ACCOMPLISH-1 (up to 3,600 patients) and ACCOMPLISH-2 (up to 1,100 patients with T2DM) are enrolling; topline data expected in the second half of 2028.


Analysis · GPCR · Life Sciences

The Q3 loss nearly doubled year over year as Phase 3 spending on aleniglipron ramped, but the $1.2B cash pile funds operations and key clinical milestones through end-2028, so there is no near-term financing pressure. The filing also discloses a CTO resignation effective November 13, 2026 and the terms of a new Chief Commercial Officer hire, both governance items investors will weigh against the clinical timeline.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GPCR was trading at $21.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.70 to $94.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $21.50 info
Change: +$0.090 (+0.42%) info
Market Cap: $1.527B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $21.50 info
Change: -$15.28 (-42%) info
Market Cap: $1.527B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $21.50 info
Change: -$26.10 (-55%) info
Market Cap: $1.527B info
GPCR
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $47.50
Real-time Price: $21.50 info
Change: -$26.00 (-55%) info
Market Cap: $1.527B info
GPCR
Aug 06, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.62
Real-time Price: $21.50 info
Change: -$31.12 (-59%) info
Market Cap: $1.527B info